Crystal structure of SARS-CoV-2 main protease in complex with a Chinese herb inhibitor shikonin
Preprint
Abstract
Main protease (M pro , also known as 3CLpro) has a major role in the replication of coronavirus life cycle and is one of the most important drug targets for anticoronavirus agents. Here we report the crystal structure of main protease of SARS-CoV-2 bound to a previously identified Chinese herb inhibitor shikonin at 2.45 angstrom resolution. Although the structure revealed here shares similar overall structure with other published structures, there are several key differences which highlight potential features that could be exploited. The catalytic dyad His41-Cys145 undergoes dramatic conformational changes, and the structure reveals an unusual arrangement of oxyanion loop stabilized by the substrate. Binding to shikonin and binding of covalent inhibitors show different binding modes, suggesting a diversity in inhibitor binding. As we learn more about different binding modes and their structure-function relationships, it is probable that we can design more effective and specific drugs with high potency that can serve as effect SARS-CoV-2 anti-viral agents.Keywords
This publication has 9 references indexed in Scilit:
- Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main proteaseScience, 2020
- Structure of SARS-CoV-2 main protease in the apo state reveals the inactive conformationbioRxiv, 2020
- Structural basis for the inhibition of SARS-CoV-2 main protease by antineoplastic drug carmofurNature Structural & Molecular Biology, 2020
- Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitorsScience, 2020
- Discovery of baicalin and baicalein as novel, natural product inhibitors of SARS-CoV-2 3CL protease in vitrobioRxiv, 2020
- Structure of Mpro from SARS-CoV-2 and discovery of its inhibitorsNature, 2020
- Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor bindingThe Lancet, 2020
- Coronaviruses — drug discovery and therapeutic optionsNature Reviews Drug Discovery, 2016
- Shikonins, Phytocompounds from Lithospermum erythrorhizon, Inhibit the Transcriptional Activation of Human Tumor Necrosis Factor α Promoter in VivoJournal of Biological Chemistry, 2004